Based on the analysis of modern publications and clinical data, chronic prostatitis is considered a complex disease that can lead to a number of complications that significantly affect the patient’s quality of life. The main complications of chronic prostatitis include:
1. Urinary system disorders:
– Recurrent urinary tract infections: Frequent exacerbations of inflammation can lead to repeated infections of the bladder, urethra and kidneys.
– Dyspepsia and urodynamic disorders: Patients may complain of painful and frequent urination, a feeling of incomplete emptying of the bladder, as well as a decrease or change in the strength of the urine stream.
2. Chronic pelvic pain:
– Constant or periodic pain in the pelvic area, lower back, perineum, genitals. This pain can develop into a chronic pain syndrome, which complicates both physical activity and the patient’s emotional state.
3. Sexual dysfunctions:
– Erectile dysfunction: Chronic inflammation and associated stress can negatively affect potency.
– Painful ejaculation and decreased libido: Pain during ejaculation and general discomfort also occur with a long-term course of the disease, which affects sexual life and the quality of relationships.
4. Psycho Emotional disorders:
– Constant discomfort and pain are often accompanied by increased anxiety, irritability and depressive states, which can lead to a deterioration in the general psychological state.
5. Fibrosis and structural changes in the prostate gland:
– With prolonged inflammation, fibrous changes may develop, which leads to changes in the tissue of the gland, disruption of its normal functioning and can contribute to further deterioration of the urodynamics of the urinary system.
6. Recurrent exacerbations:
– The chronic nature of the disease often involves recurrent exacerbations that require long-term and ongoing therapy, and in some cases, a change in the treatment regimen or a combination of therapeutic approaches.
OBSERVE NEW: PROTOCOL OF CHRONIC PROSTATITIS THERAPY
Why stem cells are highly effective in treatment of chronic prostatitis
The use of stem cells in the treatment of chronic prostatitis has several unique features that distinguish this approach from traditional methods of therapy. Below are the main aspects that explain their uniqueness:
Regulation of inflammation and immunomodulation
Stem cells, in particular mesenchymal stem cells (MSCs), have a pronounced immunomodulatory effect. They are able to secrete cytokines and growth factors that suppress chronic inflammation, reduce the production of proinflammatory mediators and stimulate the secretion of anti-inflammatory factors. This is especially important for chronic prostatitis, where long-term inflammation is a key mechanism of pathology.
Regeneration of damaged tissues
Due to their regenerative capabilities, stem cells can help restore the normal structure of the prostate gland. They are able to differentiate into cells similar to prostate tissue cells, as well as stimulate their own regeneration mechanisms through paracrine action. This allows not only to reduce symptoms, but also to restore the functionality of the affected organ.
Improving the microenvironment and reducing scarring
Prolonged inflammation can lead to fibrotic changes and disruption of the tissue structure. Stem cells, by secreting a number of bioactive molecules, help normalize the microenvironment, reduce scarring and create favorable conditions for regeneration. This improves vascular nutrition and helps restore normal metabolism in the prostate tissue.
Minimization of systemic side effects
Unlike long-term drug therapy, which may cause systemic side effects (for example, with long-term use of antibiotics or non-steroidal anti-inflammatory drugs), local stem cell transplantation allows for targeted action on the affected area. This can reduce the risk of complications and minimize the undesirable effects associated with systemic therapy.
Hormonal imbalance
Often, one of the causes of chronic prostatitis is androgenic menopause in men, or a sharp decrease in the main androgens (testosterone, DHEA). Stem cells can improve the sensitivity of receptors to free testosterone, which will change the level of testosterone in the blood.
Restoration of sexual activity
The role of AR (NR3C4) in the regeneration and sexual function of the prostate is very crucial.
• NR3C4 (Androgen receptor, AR) plays a crucial role in prostate epithelial homeostasis, neurovascular integrity and sexual function.
• Dysregulation of AR expression or activity contributes to chronic prostatitis, androgen deficiency syndromes, erectile dysfunction and benign prostatic hyperplasia.
• Prostate organoids derived from stem cells and mesenchymal stem cell-based therapy
cells, can be used for tissue repair, immunomodulation and functional recovery in chronic prostatitis.
Cell and organoid approaches for prostatitis treatment
• Human iPSC-derived prostate organoids can be engineered with AR-modulating constructs for disease modeling and therapeutic applications.
• Exosome-based AR delivery. MSC exosomes carrying AR-modulating siRNA or mRNA can regulate androgen signaling in erectile dysfunction.
• Combination therapy: BM-MSC (Bone Marrow-Derived Mesenchymal Stem Cells) + lentivirus or mRNA-modulating AR or mRNA can enhance neuromuscular recovery in neurogenic dysfunction.
Long-term improvement in quality of life
Initial clinical observations and studies show that the use of stem cells can lead to a sustained reduction in pain, improvement in prostate function and an overall improvement in the quality of life of patients. This approach has the potential to change the course of chronic prostatitis, rather than just temporarily alleviate symptoms.
The growing interest in the use of stem cells in the treatment of chronic prostatitis is explained by the fact that traditional therapies often do not provide a long-term effect and complete recovery.
Overview of clinical chronic prostatitis treatment protocols
• General indicators:
Most published cases of practical use are based on small groups of patients (e.g., 10 to 40 people). Mesenchymal stem cells (MSCs) or their derivatives + endothelial cells in combination with intra/extracellular material were used, administered directly into the prostate gland or systemically.
– Results are often assessed using a chronic prostatitis symptom scale, for example, using the NIH-CPSI (Chronic Prostatitis Symptom Index).
– Study protocols report a reduction in the NIH-CPSI total score of approximately 50–70% over several months following therapy.
• Reduced inflammation and improved function:
Therapy has shown that there is a significant reduction in inflammatory markers in the prostate gland after stem cell administration.
– Patients who have received therapy often report a reduction in pain, a reduction in dyspepsia symptoms, and an improvement in urodynamic parameters (e.g., improved quality and completeness of urination).
• Improved quality of life:
In addition to objective parameters, improvements are also noted in the subjective perception of the condition – a reduction in chronic pain, a reduction in the need for ongoing medication, and an increase in overall quality of life.
LEARN MORE : Stem cells therapy for chronic prostatitis: How it works?
Statistics and quantitative data about chronic prostatitis cases treatment with stem cells
• Sample size:
Many studies are open-label trials without randomization, so statistical significance is determined based on pre- and post-procedure comparisons in small groups.
– For example, a study involving about 20 patients showed a decrease in the average NIH-CPSI score from 25-30 to 5-8 3-6 months after therapy.
• Positive results:
Positive dynamics were observed in 80-90% of patients, where a decrease in symptoms and an improvement in urodynamic parameters were recorded.
PATIENTS REVIEWS AFTER STEM CELLS THERAPY FOR CHRONIC PROSTATITIS
– In some cases, an improvement in quality of life indicators, reflected in patient questionnaires, was reported by 50-60%.
• Safety:
Side effects were usually mild and limited to local reactions at the injection site (for example, slight swelling or soreness) in 4% of patients. The safety of the therapy was fully confirmed by repeated monitoring of the patients’ condition.
Each case of chronic prostatitis treatment is individual, because the anamnesis and nature of the disease development can be different, as well as the period of the disease and complications against the background of the disease. Therefore, it is important to undergo a preliminary consultation with a doctor to determine the exact clinical situation in order to select the right combination of biomaterials for the patient for recovery.
CONTACT OUR DOCTOR
